MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial – Hagens Berman

SAN FRANCISCO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges MacroGenics, Inc. (NASDAQ: MGNX) investors who suffered substantial losses to submit your losses now. Class Period: Mar. 7, 2024 – May 9, 2024 Lead Plaintiff Deadline: Sept. 24, 2024 Visit: www.hbsslaw.com/investor-fraud/mgnx Contact the Firm Now: MGNX@hbsslaw.com 844-916-0895 Class Action Lawsuit Against MacroGenics, Inc. (MGNX): A class-action lawsuit has been filed against MacroGenics, a biotechnology company, alleging that it misled in ...